Beyond Air Faces Delisting Concerns
Ticker: XAIR · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1641631
| Field | Detail |
|---|---|
| Company | Beyond Air, Inc. (XAIR) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $1.00, $1 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-rule, regulatory
TL;DR
Beyond Air's on the chopping block - might get delisted.
AI Summary
Beyond Air, Inc. filed an 8-K on February 5, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company was formerly known as AIT Therapeutics, Inc. and KokiCare, Inc.
Why It Matters
This filing indicates potential issues with Beyond Air, Inc.'s continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, creating significant uncertainty.
Key Players & Entities
- Beyond Air, Inc. (company) — Registrant
- AIT Therapeutics, Inc. (company) — Former Company Name
- KokiCare, Inc. (company) — Former Company Name
- February 5, 2025 (date) — Report Date
FAQ
What specific listing rule or standard has Beyond Air, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Beyond Air, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What are the implications of this notice of delisting for Beyond Air, Inc. shareholders?
A delisting could lead to increased trading volatility, reduced liquidity for shares, and potentially a significant decrease in stock value if the company cannot rectify the situation.
Does the filing provide any information on steps Beyond Air, Inc. plans to take to address the delisting concerns?
This specific excerpt of the 8-K filing does not detail any specific steps Beyond Air, Inc. plans to take to address the delisting concerns.
When was Beyond Air, Inc. previously known by other names?
Beyond Air, Inc. was formerly known as AIT Therapeutics, Inc. (name change effective January 17, 2017) and KokiCare, Inc. (name change effective May 7, 2015).
What other items are included in this 8-K filing besides the delisting notice?
In addition to the notice of delisting or failure to satisfy a continued listing rule, the filing also includes Regulation FD disclosures and financial statements and exhibits.
Filing Stats: 946 words · 4 min read · ~3 pages · Grade level 12.2 · Accepted 2025-02-05 17:00:26
Key Financial Figures
- $1.00 — y did not meet the minimum bid price of $1.00 per share required for continued listin
- $1 — the Company's common stock is at least $1 per share for a minimum of ten consecut
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001493152-25-005038.txt ( ) — 245KB
- xair-20250205.xsd (EX-101.SCH) — 3KB
- xair-20250205_lab.xml (EX-101.LAB) — 33KB
- xair-20250205_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEYOND AIR, Inc. Date: February 5, 2025 By: /s/ Steven A. Lisi Name: Steven A. Lisi Title: Chief Executive Officer